Free tool
FAERS Monitor: Ibrance
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207103 or its brand name (Ibrance, Palbociclib). Reports on generic versions are filed under their own applications.
Reports
95,562
Serious
50,805
53% of reports
Hospitalization
14,535
Death reported
10,701
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue15,790
- white blood cell count decreased11,486
- neoplasm progression10,612
- nausea8,591
- death8,004
- neutropenia6,803
- alopecia6,384
- diarrhoea6,015
- asthenia3,823
- off label use3,677
- pain3,509
- decreased appetite3,508
- malaise3,365
- dyspnoea3,309
- vomiting3,175
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 2,602 |
| 2016 | 5,940 |
| 2017 | 8,621 |
| 2018 | 9,067 |
| 2019 | 11,019 |
| 2020 | 12,869 |
| 2021 | 10,117 |
| 2022 | 12,585 |
| 2023 | 10,007 |
| 2024 | 6,069 |
| 2025 | 4,727 |
| 2026 | 1,918 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,958,597 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 10,612 | 96.2 | 94.1 | 696,179 |
| white blood cell count decreasedSignal | 11,486 | 26.0 | 25.5 | 247,772 |
| neutropeniaSignal | 6,803 | 11.5 | 11.3 | 62,606 |
| alopeciaSignal | 6,384 | 7.4 | 7.2 | 34,269 |
| fatigueSignal | 15,790 | 4.5 | 4.5 | 44,270 |
| decreased appetiteSignal | 3,508 | 3.4 | 3.3 | 5,788 |
| nauseaSignal | 8,591 | 2.4 | 2.4 | 7,241 |
| astheniaSignal | 3,823 | 2.3 | 2.2 | 2,676 |
| diarrhoeaSignal | 6,015 | 2.1 | 2.0 | 3,356 |
| deathSignal | 8,004 | 2.1 | 2.0 | 4,475 |
| malaise | 3,365 | 1.7 | 1.6 | 969 |
| vomiting | 3,175 | 1.5 | 1.4 | 519 |
| dyspnoea | 3,309 | 1.3 | 1.2 | 218 |
| pain | 3,509 | 1.3 | 1.2 | 191 |
| off label use | 3,677 | 0.9 | 0.9 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.